ACADIA Pharmaceuticals' (ACAD) Market Perform Rating Reaffirmed at Oppenheimer

Oppenheimer restated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $19.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on ACAD. Mizuho cut shares of ACADIA Pharmaceuticals from […]

Related Keywords

United States ,Canada ,Zurcher Kantonalbank Zurich Cantonalbank ,James Kihara ,Stephen Davis ,Mirae Asset Global Investments Co ,Morgan Stanley ,Nasdaq ,Pharmaceuticals Stock Down ,Pharmaceuticals Inc ,Pharmaceuticals Company Profile ,Emerald Mutual Fund Advisers ,Raymond James Associates ,Pharmaceuticals Daily ,Emerald Advisers ,Royal Bank ,Free Report ,Moderate Buy ,Stock Down ,Get Free Report ,Kantonalbank Zurich Cantonalbank ,Asset Global Investments ,Emerald Mutual Fund Advisers Trust ,Mutual Fund Advisers Trust ,Acadia Pharmaceuticals ,Nasdaq Acad ,Facad ,Medical ,Reiterated Rating ,Oppenheimer Holdings Inc ,